Tenax Therapeutics (NASDAQ:TENX) Posts Earnings Results, Beats Estimates By $0.34 EPS

Tenax Therapeutics (NASDAQ:TENX) announced its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.34, Zacks reports.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $6.26 on Wednesday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.89. The firm has a 50-day moving average of $6.44 and a 200-day moving average of $5.39.

Analyst Ratings Changes

TENX has been the topic of several research analyst reports. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a report on Monday, March 10th. Finally, StockNews.com began coverage on Tenax Therapeutics in a report on Friday, March 21st. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Tenax Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.